Melatonergic agents influence the sleep-wake and circadian rhythms in healthy and psychiatric participants: a systematic review and meta-analysis of randomized controlled trials.
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
26
08
2021
accepted:
12
01
2022
revised:
08
12
2021
pubmed:
5
2
2022
medline:
22
6
2022
entrez:
4
2
2022
Statut:
ppublish
Résumé
Exogenous melatonergic agents are widely used to treat insomnia and sleep disturbance. Several studies have shown that they might also modulate circadian rhythms. The purpose of this systematic review and meta-analysis was to summarize current knowledge about the effects of melatonin supplements and melatonin agonists on the sleep-wake cycle as well as on the circadian rhythm of melatonin in healthy participants and in patients with psychiatric disorders. The following electronic databases were searched: EMBASE, PubMed, Web of Science, CINAHL, and Cochrane Library. Of the 12,719 articles, we finally selected 30 studies including 1294 healthy participants and 8 studies including 687 patients with psychiatric disorders. Cochrane risk of bias tool was used to assess the risk of bias. Using meta-ANOVA, studies on healthy participants showed advancing effects of melatonergic supplements and agonists on sleep-wake cycle according to dosing time and dosage, despite the fact that the original individual melatonin rhythm was within a normal range (fixed effect model standardized mean difference [95% Confidence Interval] = -0.639[-0.968 to -0.310]). In a limited number of randomized controlled trials with psychiatric patients, the findings seemed similar to those with healthy participants, despite the psychiatric disorders and treatment related factors affecting circadian rhythms. Given the unmet clinical need for evidence-based treatments to correct circadian rhythms in psychiatric disorders, efficacy of melatonergic agents seen in healthy participants, and similarity of findings among psychiatric patients, large scale, well-designed randomized controlled trials are needed to test efficacy on circadian parameters in psychiatric disorders.
Identifiants
pubmed: 35115662
doi: 10.1038/s41386-022-01278-5
pii: 10.1038/s41386-022-01278-5
pmc: PMC9206011
doi:
Substances chimiques
Melatonin
JL5DK93RCL
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1523-1536Informations de copyright
© 2022. The Author(s).
Références
Cajochen C, Krauchi K, Wirz-Justice A. Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol. 2003;15:432–7.
pubmed: 12622846
doi: 10.1046/j.1365-2826.2003.00989.x
Konakchieva R, Mitev Y, Almeida OF, Patchev VK. Chronic melatonin treatment counteracts glucocorticoid-induced dysregulation of the hypothalamic-pituitary-adrenal axis in the rat. Neuroendocrinology. 1998;67:171–80.
pubmed: 9630434
doi: 10.1159/000054312
van Geijlswijk IM, Korzilius HP, Smits MG. The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis. Sleep. 2010;33:1605–14.
pubmed: 21120122
pmcid: 2982730
doi: 10.1093/sleep/33.12.1605
Suhner A, Schlagenhauf P, Johnson R, Tschopp A, Steffen R. Comparative study to determine the optimal melatonin dosage form for the alleviation of jet lag. Chronobiol Int. 1998;15:655–66.
pubmed: 9844753
doi: 10.3109/07420529808993201
Spitzer RL, Terman M, Williams JBW, Terman JS, Malt UF, Singer F, et al. Jet lag: clinical features, validation of a new syndrome-specific scale, and lack of response to melatonin in a randomized, double-blind trial. Am J Psychiatry. 1999;156:1392–96.
pubmed: 10484950
doi: 10.1176/ajp.156.9.1392
Sharkey KM, Fogg LF, Eastman CI. Effects of melatonin administration on daytime sleep after simulated night shift work. J Sleep Res. 2001;10:181–92.
pubmed: 11696071
pmcid: 3679650
doi: 10.1046/j.1365-2869.2001.00256.x
Sadeghniiat-Haghighi K, Bahrami H, Aminian O, Meysami A, Khajeh-Mehrizi A. Melatonin therapy in shift workers with difficulty falling asleep: a randomized, double-blind, placebo-controlled crossover field study. Work-a J Prev Assess Rehabilitation. 2016;55:225–30.
Lockley SW, Skene DJ, James K, Thapan K, Wright J, Arendt J. Melatonin administration can entrain the free-running circadian system of blind subjects. J Endocrinol. 2000;164:R1–6.
pubmed: 10607943
doi: 10.1677/joe.0.164r001
Sack RL, Brandes RW, Kendall AR, Lewy AJ. Entrainment of free-running circadian rhythms by melatonin in blind people. N Engl J Med. 2000;343:1070–7.
pubmed: 11027741
doi: 10.1056/NEJM200010123431503
Auld F, Maschauer EL, Morrison I, Skene DJ, Riha RL. Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Sleep Med Rev. 2017;34:10–22.
pubmed: 28648359
doi: 10.1016/j.smrv.2016.06.005
Bonacci JM, Venci JV, Gandhi MA. Tasimelteon (Hetlioz): a new melatonin receptor agonist for the treatment of non-24-hour sleep-wake disorder. J Pharm Pr. 2015;28:473–8.
doi: 10.1177/0897190014544792
Rajaratnam SM, Polymeropoulos MH, Fisher DM, Roth T, Scott C, Birznieks G, et al. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet 2009;373:482–91.
pubmed: 19054552
doi: 10.1016/S0140-6736(08)61812-7
Polymeropoulos CM, Mohrman MA, Keefe MS, Brzezynski JL, Wang J, Prokosch LS, et al. Efficacy of Tasimelteon (HETLIOZ(R)) in the treatment of jet lag disorder evaluated in an 8-h phase advance model; a multicenter, randomized, double-blind, placebo-controlled trial. Front Neurol. 2020;11:611.
pubmed: 32754110
pmcid: 7381312
doi: 10.3389/fneur.2020.00611
Lockley SW, Dressman MA, Licamele L, Xiao C, Fisher DM, Flynn-Evans EE, et al. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials. Lancet. 2015;386:1754–64.
pubmed: 26466871
doi: 10.1016/S0140-6736(15)60031-9
Nishimon S, Nishimon M, Nishino S. Tasimelteon for treating non-24-h sleep-wake rhythm disorder. Expert Opin Pharmacother. 2019;20:1065–73.
pubmed: 30990759
doi: 10.1080/14656566.2019.1603293
Kuriyama A, Honda M, Hayashino Y. Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep Med. 2014;15:385–92.
pubmed: 24656909
doi: 10.1016/j.sleep.2013.11.788
Yanagihara M, Nakamura M, Usui A, Nishida S, Ito E, Okawa M, et al. The melatonin receptor agonist is effective for free-running type circadian rhythm sleep disorder: case report on two sighted patients. Tohoku J Exp Med. 2014;234:123–8.
pubmed: 25253260
doi: 10.1620/tjem.234.123
Walker WH 2nd, Walton JC, DeVries AC, Nelson RJ. Circadian rhythm disruption and mental health. Transl Psychiatry. 2020;10:28.
pubmed: 32066704
pmcid: 7026420
doi: 10.1038/s41398-020-0694-0
Melo MCA, Abreu RLC, Linhares Neto VB, de Bruin PFC, de Bruin VMS. Chronotype and circadian rhythm in bipolar disorder: a systematic review. Sleep Med Rev. 2017;34:46–58.
pubmed: 27524206
doi: 10.1016/j.smrv.2016.06.007
Melo MC, Garcia RF, Linhares Neto VB, Sa MB, de Mesquita LM, de Araujo CF, et al. Sleep and circadian alterations in people at risk for bipolar disorder: a systematic review. J Psychiatr Res. 2016;83:211–9.
pubmed: 27661417
doi: 10.1016/j.jpsychires.2016.09.005
Porcu A, Gonzalez R, McCarthy MJ. Pharmacological manipulation of the circadian clock: a possible approach to the management of bipolar disorder. CNS Drugs. 2019;33:981–99.
pubmed: 31625128
doi: 10.1007/s40263-019-00673-9
Moon JH, Cho CH, Son GH, Geum D, Chung S, Kim H, et al. Advanced circadian phase in mania and delayed circadian phase in mixed mania and depression returned to normal after treatment of bipolar disorder. EBioMedicine. 2016;11:285–95.
pubmed: 27543154
pmcid: 5049992
doi: 10.1016/j.ebiom.2016.08.019
Meyer N, Faulkner SM, McCutcheon RA, Pillinger T, Dijk DJ, MacCabe JH. Sleep and circadian rhythm disturbance in remitted schizophrenia and bipolar disorder: a systematic review and meta-analysis. Schizophr Bull. 2020;46:1126–43.
pmcid: 7505194
doi: 10.1093/schbul/sbaa024
Wulff K, Dijk DJ, Middleton B, Foster RG, Joyce EM. Sleep and circadian rhythm disruption in schizophrenia. Br J Psychiatry. 2012;200:308–16.
pubmed: 22194182
pmcid: 3317037
doi: 10.1192/bjp.bp.111.096321
Monteleone P, Martiadis V, Maj M. Circadian rhythms and treatment implications in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1569–74.
pubmed: 20691746
doi: 10.1016/j.pnpbp.2010.07.028
Duncan WC Jr. Circadian rhythms and the pharmacology of affective illness. Pharm Ther. 1996;71:253–312.
doi: 10.1016/S0163-7258(96)00092-7
Parry BL, Newton RP. Chronobiological basis of female-specific mood disorders. Neuropsychopharmacology 2001;25(5 Suppl):S102–S8.
pubmed: 11682284
doi: 10.1016/S0893-133X(01)00340-2
Norbury R. Diurnal preference and depressive symptomatology: a meta-analysis. Sci Rep. 2021;11:12003.
pubmed: 34099766
pmcid: 8184740
doi: 10.1038/s41598-021-91205-3
Coogan AN, Thome J. Chronotherapeutics and psychiatry: setting the clock to relieve the symptoms. World J Biol Psychiatry. 2011;12(Suppl 1):S40–3.
doi: 10.3109/15622975.2011.598389
Bertrand L, d’Ortho MP, Reynaud E, Lejoyeux M, Bourgin P, Geoffroy PA. Polysomnography in seasonal affective disorder: a systematic review and meta-analysis. J Affect Disord. 2021;292:405–15.
pubmed: 34144365
doi: 10.1016/j.jad.2021.05.080
Potter GD, Skene DJ, Arendt J, Cade JE, Grant PJ, Hardie LJ. Circadian rhythm and sleep disruption: causes, metabolic consequences, and countermeasures. Endocr Rev. 2016;37:584–608.
pubmed: 27763782
pmcid: 5142605
doi: 10.1210/er.2016-1083
Goel N, Stunkard AJ, Rogers NL, Van Dongen HP, Allison KC, O’Reardon JP, et al. Circadian rhythm profiles in women with night eating syndrome. J Biol Rhythms. 2009;2485–94.
pubmed: 19150931
pmcid: 3564642
doi: 10.1177/0748730408328914
Roveda E, Montaruli A, Galasso L, Pesenti C, Bruno E, Pasanisi P, et al. Rest-activity circadian rhythm and sleep quality in patients with binge eating disorder. Chronobiol Int. 2018;35:198–207.
pubmed: 29144185
doi: 10.1080/07420528.2017.1392549
Linnaranta O, Bourguignon C, Crescenzi O, Sibthorpe D, Buyukkurt A, Steiger H, et al. Late and instable sleep phasing is associated with irregular eating patterns in eating disorders. Ann Behav Med. 2020;54:680–90.
pubmed: 32211873
pmcid: 7459186
doi: 10.1093/abm/kaaa012
Coogan AN, Baird AL, Popa-Wagner A, Thome J. Circadian rhythms and attention deficit hyperactivity disorder: the what, the when and the why. Prog Neuropsychopharmacol Biol Psychiatry. 2016;67:74–81.
pubmed: 26776072
doi: 10.1016/j.pnpbp.2016.01.006
Tonetti L, Conca A, Giupponi G, Filardi M, Natale V. Circadian activity rhythm in adult attention-deficit hyperactivity disorder. J Psychiatr Res. 2018;103:1–4.
pubmed: 29753192
doi: 10.1016/j.jpsychires.2018.05.002
Walters AS, Silvestri R, Zucconi M, Chandrashekariah R, Konofal E. Review of the possible relationship and hypothetical links between attention deficit hyperactivity disorder (ADHD) and the simple sleep related movement disorders, parasomnias, hypersomnias, and circadian rhythm disorders. J Clin Sleep Med. 2008;4:591–600.
pubmed: 19110891
pmcid: 2603539
doi: 10.5664/jcsm.27356
McGowan NM, Goodwin GM, Bilderbeck AC, Saunders KEA. Circadian rest-activity patterns in bipolar disorder and borderline personality disorder. Transl Psychiatry. 2019;9:195.
pubmed: 31431612
pmcid: 6702232
doi: 10.1038/s41398-019-0526-2
Kawato M, Fujita K, Suzuki R, Winfree AT. A three-oscillator model of the human circadian system controlling the core temperature rhythm and the sleep-wake cycle. J Theor Biol. 1982;98:369–92.
pubmed: 7176677
doi: 10.1016/0022-5193(82)90125-4
Ancoli-Israel S, Cole R, Alessi C, Chambers M, Moorcroft W, Pollak CP. The role of actigraphy in the study of sleep and circadian rhythms. Sleep. 2003;26:342–92.
pubmed: 12749557
doi: 10.1093/sleep/26.3.342
Kushida CA, Littner MR, Morgenthaler T, Alessi CA, Bailey D, Coleman J Jr., et al. Practice parameters for the indications for polysomnography and related procedures: an update for 2005. Sleep. 2005;28:499–521.
pubmed: 16171294
doi: 10.1093/sleep/28.4.499
Dueck A, Reis O, Bastian M, van Treeck L, Weirich S, Haessler F, et al. Feasibility of a complex setting for assessing sleep and circadian rhythmicity in a fragile X cohort. Front Psychiatry. 2020;11:361.
pubmed: 32477175
pmcid: 7240033
doi: 10.3389/fpsyt.2020.00361
Marino M, Li Y, Rueschman MN, Winkelman JW, Ellenbogen JM, Solet JM, et al. Measuring sleep: accuracy, sensitivity, and specificity of wrist actigraphy compared to polysomnography. Sleep. 2013;36:1747–55.
pubmed: 24179309
pmcid: 3792393
doi: 10.5665/sleep.3142
Roomkham S, Lovell D, Cheung J, Perrin D. Promises and challenges in the use of consumer-grade devices for sleep monitoring. IEEE Rev Biomed Eng. 2018;11:53–67.
pubmed: 29993607
doi: 10.1109/RBME.2018.2811735
Newell J, Mairesse O, Verbanck P, Neu D. Is a one-night stay in the lab really enough to conclude? First-night effect and night-to-night variability in polysomnographic recordings among different clinical population samples. Psychiatry Res. 2012;200:795–801.
pubmed: 22901399
doi: 10.1016/j.psychres.2012.07.045
van Hees VT, Sabia S, Jones SE, Wood AR, Anderson KN, Kivimaki M, et al. Estimating sleep parameters using an accelerometer without sleep diary. Sci Rep. 2018;8:12975.
pubmed: 30154500
pmcid: 6113241
doi: 10.1038/s41598-018-31266-z
Lavin-Gonzalez P, Bourguignon C, Crescenzi O, Beaulieu S, Storch KF, Linnaranta O. Inactograms and objective sleep measures as means to capture subjective sleep problems in patients with a bipolar disorder. Bipolar Disord. 2020;22:722–30.
Pandi-Perumal SR, Smits M, Spence W, Srinivasan V, Cardinali DP, Lowe AD, et al. Dim light melatonin onset (DLMO): a tool for the analysis of circadian phase in human sleep and chronobiological disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1–11.
pubmed: 16884842
doi: 10.1016/j.pnpbp.2006.06.020
Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev. 2005;9:41–50.
pubmed: 15649737
doi: 10.1016/j.smrv.2004.06.004
Van Geijlswijk IM, Korzilius HPLM, Smits MG. The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis. Sleep. 2010;33:1605–14.
pubmed: 21120122
pmcid: 2982730
doi: 10.1093/sleep/33.12.1605
Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. Focus (Am Psychiatr Publ). 2018;16:113–8.
Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
pubmed: 22008217
pmcid: 3196245
doi: 10.1136/bmj.d5928
Rucker G, Cates CJ, Schwarzer G. Methods for including information from multi-arm trials in pairwise meta-analysis. Res Synth Methods. 2017;8:392–403.
pubmed: 28759708
doi: 10.1002/jrsm.1259
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.
pubmed: 12958120
pmcid: 192859
doi: 10.1136/bmj.327.7414.557
Melsen WG, Bootsma MC, Rovers MM, Bonten MJ. The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses. Clin Microbiol Infect. 2014;20:123–9.
pubmed: 24320992
doi: 10.1111/1469-0691.12494
Tani H, Takasu S, Uchida H, Suzuki T, Mimura M, Takeuchi H. Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials. Neuropsychopharmacology. 2020;45:887–901.
pubmed: 31770770
doi: 10.1038/s41386-019-0573-7
Arbon EL, Knurowska M, Dijk DJ. Randomised clinical trial of the effects of prolonged-release melatonin, temazepam and zolpidem on slow-wave activity during sleep in healthy people. J Psychopharmacol. 2015;29:764–76.
pubmed: 25922426
doi: 10.1177/0269881115581963
Attenburrow MEJ, Cowen PJ, Sharpley AL. Low dose melatonin improves sleep in healthy middle-aged subjects. Psychopharmacology. 1996;126:179–81.
pubmed: 8856838
doi: 10.1007/BF02246354
Attenburrow MEJ, Dowling BA, Sargent PA, Sharpley AL, Cowen PJ. Melatonin phase advances circadian rhythm. Psychopharmacology. 1995;121:503–5.
pubmed: 8619016
doi: 10.1007/BF02246501
Burgess HJ, Revell VL, Molina TA, Eastman CI. Human phase response curves to three days of daily melatonin: 0.5 mg Versus 3.0 mg. J Clin Endocrinol Metab. 2010;95:3325–31.
pubmed: 20410229
pmcid: 2928909
doi: 10.1210/jc.2009-2590
Cajochen C, Kräuchi K, Von Arx MA, Möri D, Graw P, Wirz-Justice A. Daytime melatonin administration enhances sleepiness and theta/alpha activity in the waking EEG. Neurosci Lett. 1996;207:209–13.
pubmed: 8728487
doi: 10.1016/0304-3940(96)12517-9
Deacon S, English J, Arendt J. Acute phase-shifting effects of melatonin associated with suppression of core body temperature in humans. Neurosci Lett. 1994;178:32–4.
pubmed: 7816333
doi: 10.1016/0304-3940(94)90282-8
Dijk DJ, Roth C, Landolt HP, Werth E, Aeppli M, Achermann P, et al. Melatonin effect on daytime sleep in men: suppression of EEG low frequency activity and enhancement of spindle frequency activity. Neurosci Lett. 1995;201:13–6.
pubmed: 8830301
doi: 10.1016/0304-3940(95)12118-N
Dollins AB, Zhdanova IV, Wurtman RJ, Lynch HJ, Deng MH. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci USA. 1994;91:1824–8.
pubmed: 8127888
pmcid: 43256
doi: 10.1073/pnas.91.5.1824
Fischer S, Smolnik R, Herms M, Born J, Fehm HL. Melatonin acutely improves the neuroendocrine architecture of sleep in blind individuals. J Clin Endocrinol Metab. 2003;88:5315–20.
pubmed: 14602767
doi: 10.1210/jc.2003-030540
Holmes AL, Gilbert SS, Dawson D. Melatonin and zopiclone: the relationship between sleep propensity and body temperature. Sleep 2002;25:301–6.
pubmed: 12003160
doi: 10.1093/sleep/25.3.301
Hughes RJ, Badia P. Sleep-promoting and hypothermic effects of daytime melatonin administration in humans. Sleep. 1997;20:124–31.
pubmed: 9143072
doi: 10.1093/sleep/20.2.124
Kräuchi K, Cajochen C, Möri D, Graw P, Wirz-Justice A. Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol - Regulatory Integr Comp Physiol. 1997;272:R1178–R88. 4 41-4.
doi: 10.1152/ajpregu.1997.272.4.R1178
Markwald RR, Lee-Chiong TL, Burke TM, Snider JA, Wright KP Jr. Effects of the melatonin MT-1/MT-2 agonist ramelteon on daytime body temperature and sleep. Sleep. 2010;33:825–31.
pubmed: 20550024
pmcid: 2881716
doi: 10.1093/sleep/33.6.825
Matsumoto M. The hypnotic effects of melatonin treatment on diurnal sleep in humans. Psychiatry Clin Neurosci. 1999;53:243–5.
pubmed: 10459700
doi: 10.1046/j.1440-1819.1999.00480.x
Middleton B, Arendt J, Stone BM. Complex effects of melatonin on human circadian rhythms in constant dim light. J Biol Rhythms. 1997;12:467–77.
pubmed: 9376645
doi: 10.1177/074873049701200508
Mishima K, Satoh K, Shimizu T, Hishikawa Y. Hypnotic and hypothermic action of daytime-administered melatonin. Psychopharmacology. 1997;133:168–71.
pubmed: 9342783
doi: 10.1007/s002130050387
Nave R, Peled R, Lavie P. Melatonin improves evening napping. Eur J Pharmacol. 1995;275:213–6.
pubmed: 7796857
doi: 10.1016/0014-2999(94)00769-4
Rajaratnam SM, Polymeropoulos MH, Fisher DM, Roth T, Scott C, Birznieks G, et al. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet. 2009; 373 North American Edition:482–91.
Rajaratnam SMW, Dijk DJ, Middleton B, Stone BM, Arendt J. Melatonin phase-shifts human circadian rhythms with no evidence of changes in the duration of endogenous melatonin secretion or the 24-hour production of reproductive hormones. J Clin Endocrinol Metab. 2003;88:4303–9.
pubmed: 12970302
doi: 10.1210/jc.2003-030460
Reid K, Van Den Heuvel C, Dawson D. Day-time melatonin administration: effects on core temperature and sleep onset latency. J Sleep Res. 1996;5:150–4.
pubmed: 8956204
doi: 10.1046/j.1365-2869.1996.t01-1-00006.x
Richardson GS, Zee PC, Wang-Weigand S, Rodriguez L, Peng X. Circadian phase-shifting effects of repeated ramelteon administration in healthy adults. J Clin Sleep Med. 2008;4:456–61.
pubmed: 18853704
pmcid: 2576313
doi: 10.5664/jcsm.27282
Roth T, Stubbs C, Walsh JK. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep. 2005;28:303–7.
pubmed: 16173650
Satoh K, Mishima K. Hypothermic action of exogenously administered melatonin is dose-dependent in humans. Clin Neuropharmacol. 2001;24:334–40.
pubmed: 11801808
doi: 10.1097/00002826-200111000-00004
Seabra WDV, Bignotto M, Pinto LR, Tufik S. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J Pineal Res. 2000;29:193–200.
pubmed: 11068941
doi: 10.1034/j.1600-0633.2002.290401.x
Stone BM, Turner C, Mills SL, Nicholson AN. Hypnotic activity of melatonin. Sleep. 2000;23:663–9.
pubmed: 10947034
doi: 10.1093/sleep/23.5.1i
Terlo L, Laudon M, Tarasch R, Schatz T, Caine YG, Zisapel N. Effects of low doses of melatonin on late afternoon napping and mood. Biol Rhythm Res. 1997;28:2–15.
doi: 10.1076/brhm.28.1.2.12980
Waldhauser F, Saletu B, Trinchard-Lugan I. Sleep laboratory investigations on hypnotic properties of melatonin. Psychopharmacology. 1990;100:222–6.
pubmed: 2305009
doi: 10.1007/BF02244410
Wirz-Justice A, Werth E, Renz C, Muller S, Krauchi K. No evidence for a phase delay in human circadian rhythms after a single morning melatonin administration. J Pineal Res. 2002;32:1–5.
pubmed: 11841593
doi: 10.1034/j.1600-079x.2002.10808.x
Wright J, Aldhous M, Franey C, English J, Arendt J. The effects of exogenous melatonin on endocrine function in man. Clin Endocrinol. 1986;24:375–82.
doi: 10.1111/j.1365-2265.1986.tb01641.x
Zhdanova IV, Wurtman RJ, Lynch HJ, Ives JR, Dollins AB, Morabito C, et al. Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther. 1995;57:552–8.
pubmed: 7768078
doi: 10.1016/0009-9236(95)90040-3
Serfaty MA, Osborne D, Buszewicz MJ, Blizard R, Raven PW. A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood. Int Clin Psychopharmacol. 2010;25:132–42.
pubmed: 20195158
doi: 10.1097/YIC.0b013e32832c260b
Shamir E, Laudon M, Barak Y, Anis Y, Rotenberg V, Elizur A, et al. Melatonin improves sleep quality of patients with chronic schizophrenia. J Clin Psychiatry. 2000;61:373–7.
pubmed: 10847313
doi: 10.4088/JCP.v61n0509
Shamir E, Rotenberg VS, Laudon M, Zisapel N, Elizur A. First-night effect of melatonin treatment in patients with chronic schizophrenia. J Clin Psychopharmacol. 2000;20:691–4.
pubmed: 11106143
doi: 10.1097/00004714-200012000-00017
Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry. 2010;71:109–20.
pubmed: 20193645
doi: 10.4088/JCP.09m05347blu
Quera-Salva MA, Hajak G, Philip P, Montplaisir J, Keufer-Le Gall S, Laredo J, et al. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol. 2011;26:252–62.
pubmed: 21829106
doi: 10.1097/YIC.0b013e328349b117
Wulff K, Laigle L, Hajak G, Kasper S. Preliminary findings of the rest-activity cycles in patients with major depression following agomelatine and sertraline treatment. Eur Neuropsychopharmacol. 2012;22:S264.
doi: 10.1016/S0924-977X(12)70398-X
Saletu B, Anderer P, Saletu M, Rosales-Rodriguez S, Saletu-Zyhlarz G. Acute effects of agomelatine on sleep and awakening in major depression: Controlled polysomnographic and psychometric studies. J Sleep Res. 2012;21:25.
Fargason RE, Gamble K, Avis KT, Besing RC, Cherry Jackson W, Cates ME, et al. Ramelteon for insomnia related to attention-deficit/ hyperactivity disorder (ADHD). Psychopharmacol Bull. 2011;44:32–53.
Mishra A, Maiti R, Mishra BR, Jena M, Nath S, Sahu P. Effect of add-on ramelteon therapy on sleep and circadian rhythm disruption in patients with schizophrenia: a randomized controlled trial. Eur Neuropsychopharmacol. 2020;31:109–18.
pubmed: 31831203
doi: 10.1016/j.euroneuro.2019.11.008
Chattoraj A, Liu T, Zhang LS, Huang Z, Borjigin J. Melatonin formation in mammals: in vivo perspectives. Rev Endocr Metab Disord. 2009;10:237–43.
pubmed: 20024626
pmcid: 2843929
doi: 10.1007/s11154-009-9125-5
Pinto LR Jr., Seabra Mde L, Tufik S. Different criteria of sleep latency and the effect of melatonin on sleep consolidation. Sleep. 2004;27:1089–92.
pubmed: 15532202
doi: 10.1093/sleep/27.6.1089
Wichniak A, Wierzbicka A, Walecka M, Jernajczyk W. Effects of antidepressants on sleep. Curr Psychiatry Rep. 2017;19:63.
pubmed: 28791566
pmcid: 5548844
doi: 10.1007/s11920-017-0816-4
Moon E, Lavin P, Storch KF, Linnaranta O. Effects of antipsychotics on circadian rhythms in humans: a systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2021;108:110162.
pubmed: 33152385
doi: 10.1016/j.pnpbp.2020.110162
Campbell R, Chabot I, Rousseau B, Bridge D, Nicol G, Meier G. Understanding the unmet needs in insomnia treatment: a systematic literature review of real-world evidence. Int J Neurosci. 2021. https://doi.org/10.1080/00207454.2021.1995383 . [Online ahead of print].
Singh SP, Singh V, Kar N. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int J Neuropsychopharmacol. 2012;15:417–28.
pubmed: 21859514
doi: 10.1017/S1461145711001301
Kishi T, Nomura I, Sakuma K, Kitajima T, Mishima K, Iwata N. Melatonin receptor agonists-ramelteon and melatonin-for bipolar disorder: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials. Neuropsychiatr Dis Treat. 2019;15:1479–86.
pubmed: 31239683
pmcid: 6553999
doi: 10.2147/NDT.S198899
Kishi T, Nishiyama H, Kimura Y, Sadaka T, Terada A, Tatsumi Y, et al. Melatonin receptor agonists for bipolar mania: a systematic review and meta-analyses of double-blind randomized placebo-controlled trials. Bipolar Disord. 2021;23:301–2.
pubmed: 33629413
doi: 10.1111/bdi.13064
Lyall LM, Wyse CA, Graham N, Ferguson A, Lyall DM, Cullen B, et al. Association of disrupted circadian rhythmicity with mood disorders, subjective wellbeing, and cognitive function: a cross-sectional study of 91 105 participants from the UK Biobank. Lancet. Psychiatry 2018;5:507–14.
pubmed: 29776774
Quera Salva MA, Hartley S. Mood disorders, circadian rhythms, melatonin and melatonin agonists. J Cent Nerv Syst Dis. 2012;4:15–26.
pubmed: 23650464
pmcid: 3619438
Laudon M, Frydman-Marom A. Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders. Int J Mol Sci. 2014;15:15924–50.
pubmed: 25207602
pmcid: 4200764
doi: 10.3390/ijms150915924
Krauchi K, Wirz-Justice A. Circadian clues to sleep onset mechanisms. Neuropsychopharmacology. 2001;25:S92–6. 5 Suppl.
pubmed: 11682282
doi: 10.1016/S0893-133X(01)00315-3
Saxvig IW, Wilhelmsen-Langeland A, Pallesen S, Vedaa O, Nordhus IH, Sorensen E, et al. Objective measures of sleep and dim light melatonin onset in adolescents and young adults with delayed sleep phase disorder compared to healthy controls. J Sleep Res. 2013;22:365–72.
pubmed: 23363423
doi: 10.1111/jsr.12030
Murray JM, Phillips AJK, Magee M, Sletten TL, Gordon C, Lovato N, et al. Sleep regularity is associated with sleep-wake and circadian timing, and mediates daytime function in delayed sleep-wake phase disorder. Sleep Med. 2019;58:93–101.
pubmed: 31132578
doi: 10.1016/j.sleep.2019.03.009
Burgess HJ, Revell VL, Eastman CI. A three pulse phase response curve to three milligrams of melatonin in humans. J Physiol. 2008;586:639–47.
pubmed: 18006583
doi: 10.1113/jphysiol.2007.143180
Beck-Friis J, von Rosen D, Kjellman BF, Ljunggren JG, Wetterberg L. Melatonin in relation to body measures, sex, age, season and the use of drugs in patients with major affective disorders and healthy subjects. Psychoneuroendocrinology. 1984;9:261–77.
pubmed: 6494381
doi: 10.1016/0306-4530(84)90005-2
Novakova M, Prasko J, Latalova K, Sladek M, Sumova A. The circadian system of patients with bipolar disorder differs in episodes of mania and depression. Bipolar Disord. 2015;17:303–14.
pubmed: 25359533
doi: 10.1111/bdi.12270
Nurnberger JI Jr., Adkins S, Lahiri DK, Mayeda A, Hu K, Lewy A, et al. Melatonin suppression by light in euthymic bipolar and unipolar patients. Arch Gen Psychiatry. 2000;57:572–9.
pubmed: 10839335
doi: 10.1001/archpsyc.57.6.572
Cuthbert BN. Research Domain Criteria: toward future psychiatric nosologies. Dialogues Clin Neurosci. 2015;17:89–97.
pubmed: 25987867
pmcid: 4421905
doi: 10.31887/DCNS.2015.17.1/bcuthbert